EP999 Bevacizumab-related gastrointestinal perforation in patients with three or more prior chemotherapy regimens: a real-world experience

Introduction/Background Associations between the number of prior chemotherapy (CT) regimens and gastrointestinal (GI) perforation in patients receiving bevacizumab treatment has not been fully investigated. The aim of the study was to investigate the impact of ≥3 prior Methodology We retrospectively investigated the medical records of 133 patients with gynecological cancer who received bevacizumab-containing treatment. Bevacizumab was intravenously administered at a dose of 15 mg/kg every 4 weeks. Incidence of GI perforation was compared between ≤2 and ≥3 prior CT groups. Results Twenty-three (17.3%) patients had a history of ≥3 CT; these patients received bevacizumab at 4-week intervals. The percentage of patients with prior surgery was significantly higher in the ≥3 prior CT group (70.0% vs, 95.7%, P=0.008), while those with prior bowel resection was significantly higher in the ≥3 prior CT group (12.7% vs. 30.4%, P=0.034). There was no significant difference in the mean number of bevacizumab cycles between the two groups (8.9 vs. 10.7, P=0.19). While GI perforation was observed in three (2.7%) patients in the ≤2 prior CT group, no GI perforation was found in the ≥3 prior CT group (P>0.99). Conclusion A history of ≥3 prior CT might not increase the risk for GI perforation when bevacizumab is administered at a dose of 15 mg/kg every 4 weeks. Disclosure Nothing to disclose.